Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated:  1/12/2018
Virginia Cancer Specialists, PC
316
mi
from 43215
Fairfax, VA
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated: 1/12/2018
Virginia Cancer Specialists, PC
316
mi
from 43215
Fairfax, VA
Click here to add this to my saved trials
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated:  1/12/2018
Quest Research
176
mi
from 43215
Royal Oaks, MI
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status: Enrolling
Updated: 1/12/2018
Quest Research
176
mi
from 43215
Royal Oaks, MI
Click here to add this to my saved trials
Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer
Weekly Trastuzumab (Herceptin) and Irinotecan in Patients With HER-2 Positive Advanced Breast Cancer: A Phase II Trial
Status: Enrolling
Updated:  1/12/2018
UCSF Helen Diller Family Comprehensive Cancer Center
2108
mi
from 43215
San Francisco, CA
Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer
Weekly Trastuzumab (Herceptin) and Irinotecan in Patients With HER-2 Positive Advanced Breast Cancer: A Phase II Trial
Status: Enrolling
Updated: 1/12/2018
UCSF Helen Diller Family Comprehensive Cancer Center
2108
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
Phase II Study of Acolbifene in Pre-Menopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  1/15/2018
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
Phase II Study of Acolbifene in Pre-Menopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 1/15/2018
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer
A Phase II Study of Accelerated Hypofractionated Radiotherapy (AHF-RT) After Breast Conserving Surgery (BCS) in Medically Underserved Patients
Status: Enrolling
Updated:  1/15/2018
James Graham Brown Cancer Center
188
mi
from 43215
Louisville, KY
Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer
A Phase II Study of Accelerated Hypofractionated Radiotherapy (AHF-RT) After Breast Conserving Surgery (BCS) in Medically Underserved Patients
Status: Enrolling
Updated: 1/15/2018
James Graham Brown Cancer Center
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
University of Arkansas for Medical Sciences
624
mi
from 43215
Little Rock, AR
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
University of Arkansas for Medical Sciences
624
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Northwestern University Medical Center
274
mi
from 43215
Chicago, IL
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Northwestern University Medical Center
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Ohio State Unviersity Medical Center
0
mi
from 43215
Columbus, OH
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Ohio State Unviersity Medical Center
0
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
University of Oklahoma Health Sciences Center
841
mi
from 43215
Oklahoma City, OK
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
University of Oklahoma Health Sciences Center
841
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Univ of Washington
2006
mi
from 43215
Seattle, WA
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Univ of Washington
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Georgetown Lombardi Comprehensive Cancer Center
328
mi
from 43215
Washington,
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Georgetown Lombardi Comprehensive Cancer Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
331
mi
from 43215
Nashville, TN
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
331
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
910
mi
from 43215
Dallas, TX
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1655
mi
from 43215
Chandler, AZ
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1655
mi
from 43215
Chandler, AZ
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1610
mi
from 43215
Sedona, AZ
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1610
mi
from 43215
Sedona, AZ
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1926
mi
from 43215
La Jolla, CA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1926
mi
from 43215
La Jolla, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2017
mi
from 43215
Oxnard, CA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2017
mi
from 43215
Oxnard, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1985
mi
from 43215
Santa Monica, CA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1985
mi
from 43215
Santa Monica, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1162
mi
from 43215
Denver, CO
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
328
mi
from 43215
Washington,
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
328
mi
from 43215
Washington,
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
989
mi
from 43215
Hialeah, FL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
989
mi
from 43215
Hialeah, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
993
mi
from 43215
Miami, FL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
970
mi
from 43215
Plantation, FL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
970
mi
from 43215
Plantation, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
831
mi
from 43215
Tampa, FL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
425
mi
from 43215
Marietta, GA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
425
mi
from 43215
Marietta, GA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
561
mi
from 43215
Savannah, GA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
561
mi
from 43215
Savannah, GA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
274
mi
from 43215
Chicago, IL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
444
mi
from 43215
Quincy, IL
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
444
mi
from 43215
Quincy, IL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
784
mi
from 43215
Wichita, KA
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
784
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
188
mi
from 43215
Louisville, KY
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
163
mi
from 43215
Detroit, MI
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
163
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
206
mi
from 43215
Kalamazoo, MI
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
206
mi
from 43215
Kalamazoo, MI
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
624
mi
from 43215
Minneapolis, MN
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
618
mi
from 43215
Kansas City, MO
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
618
mi
from 43215
Kansas City, MO
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
807
mi
from 43215
Grand Island, NE
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
807
mi
from 43215
Grand Island, NE
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
682
mi
from 43215
Omaha, NE
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
418
mi
from 43215
Camden, NJ
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
418
mi
from 43215
Camden, NJ
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
476
mi
from 43215
Hackensack, NJ
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
476
mi
from 43215
Hackensack, NJ
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
1379
mi
from 43215
Farmington, NM
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
1379
mi
from 43215
Farmington, NM
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
482
mi
from 43215
Bronx, NY
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
482
mi
from 43215
Bronx, NY
Click here to add this to my saved trials